Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its industry-leading obesity test. Digbi Health is introducing innovative components to personalize nutritional and pharmacotherapy support to ensure everyone receives the right care based on their biology and lifestyle.
Understanding the Different Causes of Obesity to Personalize Treatment
The causes of obesity vary widely among individuals based on their genetics, gut microbiome, glucose metabolism and lifestyle. For some, obesity is primarily driven by insulin-related metabolic issues. For others, it stems from gut-brain axis dysfunction, influencing cravings and hunger regulation. Additionally, some individuals may experience a combination of gut-brain issues affecting satiety, mental health factors, and lifestyle constraints. By isolating these different phenotypes, Digbi Health can tailor treatment approaches more precisely, leading to 3X better weight outcomes than traditional one-size-fits-all interventions.
Building Innovation: The First Precision Biology-Based Obesity Test
Following the successful launch of its GLP Compass(™), Digbi Health continues to innovate by expanding its obesity test capabilities in 2025. These enhancements guide care providers and benefit patients by ensuring they receive the most personalized and effective nutrition-first obesity care.
GLP Compass – Provides members with clarity on their weight loss journey by determining who truly needs GLP-1 drugs versus those who can achieve sustainable weight loss through food-as-medicine. This ensures patients avoid unnecessary medication, employers, and health plans’ unnecessary costs while maximizing natural and sustainable health improvements.
GLP Compass is developed using AI and millions of data points across 10,000 patients’ biology, food, medical, and lifestyle data over 52 weeks and sets a new standard in obesity management. It offers precision-driven solutions that empower doctors and individuals to take control of their health while optimizing pharmacotherapy.
“Our goal is to provide personalized and AI-based nutrition-first care for the top four food-related illnesses—Obesity, Type 2 diabetes, gastrointestinal disorders, and mental health,” said Ranjan Sinha, Founder and CEO at Digbi Health. “By expanding our industry-leading obesity test, we reinforce our commitment to innovation and safety-first AI-based care.”
